Comments
FDC has informed the exchanges that the company continues with its approved status from UK MHRA (Medicines and Healthcare Products Regulatory Agency) for its ophthalmic manufacturing facility at Waluj, Aurangabad. The observation was based on the recent Good Manufacturing Practice (GMP) inspection held at the plant. The pharmaceuticals major had reported a net profit of ₹64.87 crore for the quarter ended September 2017 on revenues of ₹304.63 crore.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.